Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23146200 | 0.79 | TDP1 (0.38) | TDP1ALDH1A1KDM4EKCNJ1LTA4H | |
| SCHEMBL20500556 | 0.78 | DUT (0.33) | DUTCA12CA1CA2CA9 | |
| SCHEMBL7713830 | 0.73 | TDP1 (0.41) | TDP1ALDH1A1KDM4EKCNJ1 | |
| SCHEMBL22020713 | 0.72 | TDP1 (0.32) | TDP1ALDH1A1KDM4E | |
| SCHEMBL2141162 | 0.71 | ALDH1A1 (0.41) | DUTCA12CA1CA2CA9 | |
| SCHEMBL16935016 | 0.69 | ALDH1A1 (0.37) | TDP1ALDH1A1KDM4EKCNJ1 | |
| SCHEMBL4892445 | 0.69 | — | — | |
| SCHEMBL664995 | 0.69 | ALDH1A1 (0.50) | DUTALDH1A1KDM4E | |
| SCHEMBL20391402 | 0.69 | DUT (0.42) | DUTALDH1A1 | |
| SCHEMBL738265 | 0.68 | DUT (0.35) | DUTCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | DUT 1352/4885TDP1 2457/4885CA12 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.